AdaptHealth Corp. (NASDAQ:AHCO) Receives $27.17 Average Target Price from Brokerages

AdaptHealth Corp. (NASDAQ:AHCOGet Rating) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $27.17.

AHCO has been the subject of several research reports. Truist Financial boosted their price objective on shares of AdaptHealth from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of AdaptHealth from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. TheStreet raised shares of AdaptHealth from a “d+” rating to a “c-” rating in a research note on Tuesday, August 2nd. Finally, SVB Leerink lifted their target price on shares of AdaptHealth from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, August 10th.

AdaptHealth Stock Down 1.9 %

AHCO stock opened at $19.99 on Tuesday. The stock has a market capitalization of $2.68 billion, a P/E ratio of 38.44, a PEG ratio of 0.36 and a beta of 0.59. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.15 and a current ratio of 1.39. AdaptHealth has a one year low of $11.40 and a one year high of $28.75. The company has a 50 day moving average price of $20.93 and a two-hundred day moving average price of $18.12.

AdaptHealth (NASDAQ:AHCOGet Rating) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.23). AdaptHealth had a net margin of 4.91% and a return on equity of 6.49%. The company had revenue of $727.61 million for the quarter, compared to analysts’ expectations of $724.27 million. During the same period in the prior year, the firm earned ($0.11) earnings per share. The firm’s quarterly revenue was up 17.9% on a year-over-year basis. As a group, sell-side analysts expect that AdaptHealth will post 1.32 EPS for the current year.

Insider Activity at AdaptHealth

In related news, major shareholder Everest Hill Group Inc. sold 215,382 shares of AdaptHealth stock in a transaction on Friday, August 12th. The shares were sold at an average price of $23.50, for a total transaction of $5,061,477.00. Following the transaction, the insider now owns 15,119,834 shares in the company, valued at approximately $355,316,099. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other AdaptHealth news, major shareholder Everest Hill Group Inc. sold 215,382 shares of the business’s stock in a transaction on Friday, August 12th. The shares were sold at an average price of $23.50, for a total value of $5,061,477.00. Following the transaction, the insider now owns 15,119,834 shares in the company, valued at approximately $355,316,099. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Christopher J. Joyce sold 100,000 shares of the business’s stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $22.20, for a total transaction of $2,220,000.00. Following the completion of the transaction, the general counsel now owns 106,071 shares in the company, valued at approximately $2,354,776.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 474,382 shares of company stock worth $10,938,477. 17.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AdaptHealth

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in AdaptHealth by 0.6% in the 4th quarter. Rhumbline Advisers now owns 101,502 shares of the company’s stock worth $2,483,000 after buying an additional 593 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of AdaptHealth by 96.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,710 shares of the company’s stock valued at $27,000 after purchasing an additional 840 shares in the last quarter. First Republic Investment Management Inc. raised its stake in shares of AdaptHealth by 3.8% in the 2nd quarter. First Republic Investment Management Inc. now owns 24,990 shares of the company’s stock valued at $451,000 after purchasing an additional 924 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of AdaptHealth by 6.1% in the 1st quarter. Teacher Retirement System of Texas now owns 16,197 shares of the company’s stock valued at $260,000 after purchasing an additional 927 shares in the last quarter. Finally, Covestor Ltd acquired a new stake in shares of AdaptHealth in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 75.76% of the company’s stock.

AdaptHealth Company Profile

(Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Read More

Analyst Recommendations for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.